A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

Official title

A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

Overview

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatment period: 24 weeks. * Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods). The total number of planned study visits for each participant will be 6.

Interventions

• Drug Dupilumab
  Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Primary outcome measures

• Concentration of dupilumab in serum [Time frame: Day 1 to Week 40]

Secondary outcome measures (2)

• Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) [Time frame: Date of signed ICF (2-4 weeks before Day 1) to Week 40]
• Incidence of anti-drug antibodies (ADA) to dupilumab over time [Time frame: Day 1 to Week 40]

Eligibility criteria

Inclusion criteria

• Participants must be ≥6 months to <18 years of age, at the time of signing the informed consent.
• A clinical diagnosis of prurigo nodularis (PN) at least 3 months prior to screening, an Investigator's global assessment for prurigo nodularis stage (IGA PN-S) score of ≥2 with presence of ≥6 pruriginous lesions at Baseline. The lesions should be present on ≥2 different body surface areas at Baseline.
• On the worst itch numerical rating scale (WI-NRS) (for participants aged ≥6 years to <18 years old at the screening visit) or worst-scratch/itch NRS (for participants aged ≥6 months to <6 years at the screening visit) ranging from 0 to 10, participants must have an average worst itch score of ≥7 in the 7 days prior to Day 1.

NOTE: Baseline pruritus NRS average score for maximum itch intensity will be determined based on the average of daily NRS scores for maximum intensity (the daily score ranges from 0 to 10) during the 7 days immediately preceding the Day 1/Baseline visit. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.

• Participants/Caregivers must be willing and able to complete a daily symptom e-Diary for the duration of the study.
• Contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Participants are excluded from the study if any of the following criteria apply:

• Presence of active moderate to severe lesions of atopic dermatitis (AD), and/or other skin conditions that may interfere with the PN diagnosis including but not limited to the following: scabies, psoriasis, lymphomatoid papulosis, habitual picking, dermatitis herpetiformis, sporotrichosis, and bullous disease.
• Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period.

NOTE: Participants may be rescreened after infection resolves.

• Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
• Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study.
• Planned or anticipated major surgical procedure during the participant's participation in this clinical trial.
• Participants who has taken biologic therapy/systemic immunosuppressant/ immunomodulator within 4 weeks before the screening visit or 5 half-lives, whichever is longer.
• Current participation to any clinical trial of an investigational drug or device or participation within 3 months before the screening visit or 5 half-lives of the investigational compound, whichever is longer.
• Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 14 centers

• Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400021 — Palo Alto
• Mission Dermatology Center- Site Number : 8400011 — Rancho Santa Margarita
• Pediatric Center of Excellence (PCE) - Miami Pediatric Endocrinology- Site Number : 840000 — Coral Gables
• Life Clinical Trials - Coral Springs- Site Number : 8400018 — Coral Springs
• Direct Helpers Research Center- Site Number : 8400015 — Hialeah
• SunCoast Skin Solutions - Lutz- Site Number : 8400008 — Lutz
• USF Health- Site Number : 8400003 — Tampa
• Tareen Dermatology - Eagan- Site Number : 8400022 — Eagan
• … and 6 more centers

Identifiers

NCT: NCT06293053 · PKM17836 · U1111-1287-7255

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗